Advertisement

Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients

  • P. Renard
  • J. L. Kovalski
  • I. Cochereau
  • S. Jaulerry
  • W. Williamson
  • P. P. Elena
  • M. Lablache Combier
  • C. Allaire
  • R. Siou-Mermet
Clinical Investigation

Abstract

Background

A new long-acting (LA) formulation of carteolol 2% instilled once daily has been shown to provide a therapeutic effect similar to that of the regular formulation of carteolol 2% instilled twice daily. This study was designed to test whether the new formulation reduces the systemic delivery of carteolol.

Methods

In this double-masked, randomised, intra-subject comparative study, 23 patients with bilateral primary open-angle glaucoma or bilateral ocular hypertension received sequentially, according to the randomised order of administration, each of the 2 following treatments: carteolol 2% LA once daily for 2 months and carteolol 2% regular twice daily for 2 months. Treatments were instilled in both eyes throughout the study period. At the end of each period of treatment, blood samples were taken immediately before the last morning instillation (residual time), then 30 min, 1 h, 2 h and 4 h after this instillation in order to measure the carteolol plasma concentrations.

Results

The mean values of maximal plasma concentration (Cmax), residual level and area under the curve obtained following carteolol 2% LA treatment were significantly lower than the values obtained after carteolol 2% regular treatment (mean±SD): Cmax (ng/ml): 1.72±0.85 versus 3.64±3.65; residual level (ng/ml): 0.70±0.58 versus 1.80±0.84; area under the curve (ng/ml×h): 5.50±2.66 versus 10.27±5.46. Regarding safety, two drug-related, non-serious adverse events were reported in the LA group: one case of moderate, superficial, punctate keratitis and one case of “bitter taste in the throat.” Both treatments appeared to be well tolerated.

Conclusions

The data from this study showed that the systemic delivery of carteolol is lower for the once-daily LA formulation than for the regular twice-daily formulation. Consequently, long-acting carteolol eye-drops should reduce the risk of β-blocking systemic side effects.

Keywords

Carteolol Beta-blocker Alginic acid Systemic delivery Kinetics 

Notes

Acknowledgements

The authors would like to thank R. Garraffo, pharmacist, France, for his advice on pharmacokinetics; C. Whately-Smith, statistician, UK, for reviewing the article; and all the study participants.

References

  1. 1.
    Demailly P, Allaire C, Trinquand C (2001) Ocular hypotensive efficacy and safety of once daily carteolol alginate. Br J Ophthalmol 85:921–924CrossRefPubMedGoogle Scholar
  2. 2.
    Hasenfuß G, Schäefer-Korting M, Knauf H, Mutschler E, Just H (1985) Pharmacokinetics of carteolol in relation to renal function. Eur J Clin Pharmacol 29:461–465CrossRefPubMedGoogle Scholar
  3. 3.
    Ishii Y, Nakamura K, Matsuki S, Uemura N, Muraguchi R, Nakagawa M, Nakano S, Nakatsuka K (2002) Pharmacokinetic and pharmacodynamic differences between ocular and nasal instillation of carteolol on intraocular pressure and heart rate in Japanese men with high CYP2D6 activity. J Clin Pharmacol 42:1020–1026PubMedGoogle Scholar
  4. 4.
    Konstas AGP, Maskaleris G, Gratsonidis S, Sardelli C (2000) Compliance and viewpoint of glaucoma patients in Greece. Royal college of ophthalmologists. Eye 14:752–756PubMedGoogle Scholar
  5. 5.
    Lesar TS (1987) Comparison of ophthalmic β-blocking agents. Clin Pharm 6:451–463PubMedGoogle Scholar
  6. 6.
    Morita S, Iinuma M, Kido M, Sakuragi S, Kohri H, Nishino H (1977) Metabolic fate of carteolol hydrochloride, (OPC-1085) VIII, a new β-adrenergic blocking agent. Drug Res 27:2380–2383Google Scholar
  7. 7.
    Negishi C, Kanai A, Nakajima A, Funahashi M, Kitazawa Y (1981) Ocular effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients. Jpn J Ophthalmol 25:464–476Google Scholar
  8. 8.
    Norell SE (1981)Monitoring compliance with pilocarpine therapy. Am J Ophthalmol 92:727–731PubMedGoogle Scholar
  9. 9.
    Note for guidance on the investigation of bio-availability and bio-equivalence. E.M.E.A. 2001Google Scholar
  10. 10.
    Ringham GL, Luther RR, Senello LT, Schambelan M, Humphreys MH (1985) A pharmacokinetic evaluation of carteolol in patients with impaired renal function. J Clin Pharmacol 25:468Google Scholar
  11. 11.
    Ringham GL, Senello LT, Jordan DC, Luther RR, Klepper MJ, Finley RA, Tolman KG (1987) Pharmacokinetics of carteolol in subjects of different ages. J Clin Pharmacol 27:715Google Scholar
  12. 12.
    Séchoy O, Tissié G, Sébastian C, Maurin F, Driot JY, Trinquand C (2000) A new long acting ophthalmic formulation of carteolol containing alginic acid. Int J Pharm 207:109–116CrossRefPubMedGoogle Scholar
  13. 13.
    Senello LT, Finley RA, Chu SY, Bunnell ST, Sonders RC, Ringham GL, Luther RR, Humphreys MH, Poon AH, Schambelan M (1987) The effect of impaired renal function on the multiple dose clinical pharmacokinetics of carteolol. Adv Ther 4:298–308Google Scholar
  14. 14.
    Schnarr K-D (1988) Vergleichende multizentrische Untersuchung von Carteolol-Augentropfen mit anderen Betablockern bei 768 Patienten unter Alltagsbedingungen. Klin Monatsbl Augenheilkd 192:167–172PubMedGoogle Scholar
  15. 15.
    Stewart WC, Shields MB, Allen RC, Lewis RA, Cohen JS, Dunbar Hoskins H, Hetherington JN, Bahr RL, Noblin JE, Delehanty JT (1991) A 3-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. Graefe Arch Clin Exp Ophthalmol 229:258–261CrossRefGoogle Scholar
  16. 16.
    Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL (1997) Efficacity of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Am J Ophthalmol 124:498–505PubMedGoogle Scholar
  17. 17.
    Tissié G, Sébastian C, Elena PP, Driot JY, Trinquand C (2002) Alginic acid effect on carteolol ocular pharmacokinetics in the pigmented rabbit. J Ocular Pharmacol Ther 18:65–73CrossRefGoogle Scholar
  18. 18.
    Trinquand C, Romanet JP, Nordmann JP, Allaire C (2003) Efficacité et tolérance du carteolol 1% à libération prolongée une fois par jour. Etude randomisée en double insu. J Fr Ophtalmol 26:131–136PubMedGoogle Scholar
  19. 19.
    Zimmerman TJ (1993) Topical ophthalmic beta-blockers: a comparative review. J Ocul Pharmacol 9:373–384PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • P. Renard
    • 1
  • J. L. Kovalski
    • 2
  • I. Cochereau
    • 3
  • S. Jaulerry
    • 4
  • W. Williamson
    • 5
  • P. P. Elena
    • 6
  • M. Lablache Combier
    • 7
  • C. Allaire
    • 7
  • R. Siou-Mermet
    • 7
  1. 1.Institut VernesParisFrance
  2. 2.HIA Clermont TonnerreBrestFrance
  3. 3.CHRUAngersFrance
  4. 4.CH Tarbes Vic BigorreTarbesFrance
  5. 5.CH François MitterrandPauFrance
  6. 6.Iris Pharma-ClirophthaLa GaudeFrance
  7. 7.Bausch & LombParisFrance

Personalised recommendations